In a recent regulatory filing that serves as an amendment to an original Form 4, Compass Therapeutics, Inc. (NASDAQ: CMPX) disclosed that its Chief Accounting Officer, Neil Lerner, purchased 15,000 shares of the company's common stock. The transaction took place on April 29, 2026, at a price of $1.89 per share, representing a total investment of $28,350.
Following this acquisition, Mr. Lerner’s direct holdings in Compass Therapeutics common stock amount to 397,500 shares. This total includes 62,500 unvested restricted stock units (RSUs) that were originally granted on January 2, 2026. These RSUs are structured to provide one share of common stock for each unit and are tied to specific service-based vesting requirements. The first of four annual installments for these units is scheduled to vest on January 2, 2027.
Market Context and Valuation
The timing of this insider purchase is notable given the current trading environment for CMPX. As of the latest data, the stock is trading at $1.77, a level that reflects a 68.9% decrease year-to-date and a decline of nearly 68% over the preceding week. Despite this volatility, analysis from InvestingPro suggests the stock may currently be undervalued. Investors are also looking toward upcoming earnings results, which are expected to be released in 13 days.
Clinical Trial Outcomes and Analyst Divergence
The recent movement in Compass Therapeutics' valuation follows the release of data from the COMPANION-002 clinical trial. This study investigated the efficacy of the drug candidate tovecimig when used in combination with paclitaxel for patients facing second-line biliary tract cancer. The results indicated a statistically significant benefit in progression-free survival, evidenced by a hazard ratio of 0.44, which corresponds to a 56% reduction in the risk of disease progression.
While the progression-free survival data was positive, it has led to a divided outlook among market analysts regarding the company's future trajectory:
- Raymond James downgraded the stock from Outperform to Market Perform, citing concerns related to overall survival outcomes.
- Stifel reduced its price target from $12.00 down to $6.00, pointing toward uncertainty regarding how the FDA might interpret the trial's secondary endpoints.
- H.C. Wainwright maintained a Buy rating with a $24.00 price target, placing emphasis on the progression-free survival results.
- Leerink Partners reiterated an Outperform rating with an $11.00 target, also highlighting the statistically significant benefits observed in the trial.
- Citizens continued to hold a Market Outperform rating.
These conflicting assessments highlight the complexities inherent in interpreting clinical data within the biotechnology sector.